AzTrials
AzTrials

AnemiaPhase 1NCT02101944

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 study testing Carfilzomib, Dexamethasone and Laboratory Biomarker Analysis in people with Anemia and Recurrent Multiple Myeloma, run by National Cancer Institute (NCI) at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Carfilzomib, Dexamethasone and Laboratory Biomarker Analysis
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
3 sitesUnited States
Study dates
9 Dec 2014to 7 May 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient must have relapsed or refractory myeloma that fits or did fit International Myeloma Working Group (IMWG) diagnostic criteria for symptomatic myeloma (although new or worsening end organ damage is not required to be eligible) as defined below:
  • Presence of clonal bone marrow plasma cells
  • Evidence of any end organ damage criteria listed below (at any time) attributed to the patient's myeloma:
  • Hypercalcemia: serum calcium > 11.5 mg/dL or
  • Renal insufficiency: serum creatinine > 2 mg/dL
  • Anemia > 2 g/dL below the lower limit of normal or a hemoglobin value < 10 g/dL
Show all 28Show fewer
  • Bone lesions: lytic lesions, severe osteopenia or pathologic fractures
  • In the safety expansion 10 patient group but not during dose escalation, patients must have measurable disease defined as any of the following:
  • Serum monoclonal protein >= 500 mg/dL by protein electrophoresis
  • > 200 mg of monoclonal protein in the urine on screening 24-hour electrophoresis
  • Serum immunoglobulin free light chain >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
  • Patients must have been previously treated with an immunomodulatory drug (IMiD) and proteasome inhibitor, must be refractory to carfilzomib defined as progression on or within 2 months of a carfilzomib-containing therapy, and must be progressing
  • Prior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registration
  • Both men and women of all races and ethnic groups are eligible for this study
  • Prior radiation is permitted; however, at least 2 weeks must have elapsed since the completion of prior radiation therapy and patients must have recovered from all radiation-associated toxicities to no greater than grade 1 at the time of registration
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible
  • Absolute neutrophil count (ANC) >= 1000/uL
  • Platelet count >= 75,000 and transfusion independent
  • Total bilirubin < 1.5 mg/dL
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal
  • Ability to understand and the willingness to sign a written informed consent document
  • Patients must be able to avoid direct contact with pregnant or nursing women, infants and immunocompromised individuals during the days of Reolysin treatment and for two days after
  • Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
  • Systolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= 50% will be eligible for enrollment
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle (if applicable)
  • The effects of Reolysin on the developing human fetus are unknown; for this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting 28 days prior to starting the study until at least 90 days following discontinuation of the trial therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Patients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least 4 weeks after stopping treatment

Who cannot join

  • Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment
  • Patients who are receiving any other therapeutic investigational agents
  • Patients previously treated on clinical trial with Reolysin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the preceding 6 months, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because protocol therapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to protocol treatment of the mother, breastfeeding should be discontinued
  • Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to < 1 year, or confound data interpretation
  • Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS) syndrome
  • Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112

Other trials in United States

About this study

Official title: Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma

This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called wild-type reovirus may be able to kill cancer cells without damaging normal cells and seems to work best when given with chemotherapy. Giving wild-type reovirus with chemotherapy may be a more effective treatment than chemotherapy alone.

Read the detailed description

PRIMARY OBJECTIVES:

  1. Determine safety and tolerability, and define the maximum tolerated dose of pelareorep (Reolysin), carfilzomib and dexamethasone in patients with relapsed multiple myeloma.

II. Obtain evidence of reovirus entry into myeloma cells via localization of reoviral ribonucleic acid (RNA) in multiple myeloma (MM) cells (in situ hybridization [ISH]), and active viral proliferation/replication via localization of reoviral capsid protein (immunohistochemistry [IHC]) in MM cells in cycle 1 day 9 bone marrow biopsies in all patients enrolled in dose escalation cohorts.

SECONDARY OBJECTIVES:

  1. Obtain preliminary data on response as determined by International Myeloma Working Group criteria after protocol therapy.

II. Obtain overall and progression free survival data for all treated patients. III. Assess cytokine arrays of peripheral blood obtained on days 1, 2, 9, 15 and once during days 22-28 of cycle 1, and day 1 of cycle 2 and each successive cycle to obtain exploratory data regarding inflammatory cytokine concentrations and their correlation with response.

IV. Investigate pretreatment cycle 1 days 1 and 9 bone marrow aspirate interferon (IFN)-beta in MM cells as a potential marker of Reolysin resistance.

  1. Measure the induction of endoplasmic reticulum (ER) stress and autophagy markers to explore their respective roles in MM cell death following combination Reolysin and carfilzomib in patients treated in all dose escalation cohorts.

VI. Evaluate pretreatment cycle 1 days 1 and 9 peripheral blood to explore the antiviral humoral response by measuring the production of neutralizing reoviral antibody (NARA) using a functional killing assay.

VII. Obtain cycle 1 day 1 pretreatment and 1 and 4 hours after treatment, and pretreatment cycle 1 days 2 and 9 peripheral blood, and pretreatment cycle 1 days 1 and 9 bone marrow aspirate samples to investigate the role of carfilzomib in modulating the antiviral immune mediated response.

OUTLINE: This is a dose escalation study of Reolysin.

Patients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks and then every 6 months thereafter.

Being tested
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
Medical subject headings
Anemia, Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CarfilzomibDrug

    Also called Carfilnat, CFZ, Kyprolis, PR-171

    Given IV

  • DexamethasoneDrug

    Also called Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PelareorepBiological

    Also called PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3

    Given IV

Study groups in NCT02101944
Study groupRoleWhat they receive
Treatment (dexamethasone, carfilzomib, Reolysin)ExperimentalPatients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Receives: Drug: Carfilzomib; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis; Biological: Pelareorep

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number and severity of adverse events

    Based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Adverse events will be perceived causal relationship to the study therapy.

    Measured: Up to 4 weeks post treatment

  2. Maximum tolerated dose of combination carfilzomib and wild-type reovirus

    Assessed by CTCAE version 5.0. Maximum tolerated dose defined as the highest dose with fewer than 33% dose limiting toxicities observed in cycle 1 or 2 evaluated using CTCAE version 5.0. Frequency distributions and other descriptive measures will form the basis of the analysis of these variables.

    Measured: Up to 28 days

  3. Number of patients who required dose modifications and/or dose delays in subsequent cycles

    Frequency distributions and other descriptive measures will form the basis of the analysis of these variables.

    Measured: Up to 4 weeks post treatment

  4. Proportion of patients who go off treatment due to adverse reactions of refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial

    Frequency distributions and other descriptive measures will form the basis of the analysis of these variables.

    Measured: Up to 4 weeks post treatment

Secondary outcomes (7)

  1. Reoviral capsid protein production via immunohistochemical analysis

    Will include graphical evaluation of these immunologic correlative markers at baseline as well as at the various timepoints.

    Measured: Up to day 9 of cycle 1

  2. Presence and location of intracellular reoviral ribonucleic acid (RNA) assessed by in situ hybridization

    Will include graphical evaluation of these immunologic correlative markers at baseline as well as at the various timepoints.

    Measured: Up to day 9 of cycle 1

  3. Number and percentage of subjects experiencing objective response

    Summary statistics will be computed for baseline biomarkers. The absolute and percent change from baseline will be calculated for each subsequent measurement. Summary statistics will be computed for each collection time point. The objective response rate will be analyzed by using a 95% confidence interval for the proportion responding at trial closure in the treated population.

    Measured: Up to 4 weeks post treatment

  4. Clinical benefit endpoint described as that portion of patients experiencing complete response, very good partial response, or partial response

    The objective response rate will be analyzed by using a 95% confidence interval for the proportion responding at trial closure in the treated population.

    Measured: Up to 4 weeks post treatment

  5. Duration of response

    This time-to-event distribution will be evaluated using the methods of Kaplan and Meier, with a focus on graphical evaluation as well as early timepoint and median estimates of survival distributions.

    Measured: Duration from first observation of partial response to the time of disease progression, up to 4 weeks post treatment

  6. Progression free survival

    This time-to-event distribution will be evaluated using the methods of Kaplan and Meier, with a focus on graphical evaluation as well as early timepoint and median estimates of survival distributions.

    Measured: Duration from start of treatment to disease progression or death, regardless of cause of death, whichever comes first, up to 2 years

  7. Time to progression

    This time-to-event distribution will be evaluated using the methods of Kaplan and Meier, with a focus on graphical evaluation as well as early timepoint and median estimates of survival distributions.

    Measured: Time from the start of the treatment until the criteria for disease progression are met, up to 4 weeks post treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2014 (estimated)
  2. Study start9 Dec 2014
  3. Primary completion5 May 2021
  4. Study completion7 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02101944
Sponsor's protocol ID
NCI-2014-00643
Other IDs
NCI-2014-00643, OSU-14031, 14031, NCI-9603, 2014C0091, 9603, 9603, P30CA016058
Status last verified
May 2024
First submitted
28 Mar 2014
Last updated
17 May 2024
Results posted
No
Data monitoring committee
Yes

Publications

  • Dona AA, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, Zhu Y, Moloudizargari M, Sharma P, Napolitano O, Winchester J, Chowdhury A, Pozhitkov A, Sanchez JF, Vahed H, Marcucci G, Coffey M, Nuovo G, Sborov DW, Pichiorri F, Hofmeister CC. Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. J Hematol Oncol. 2025 Jan 20;18(1):1. doi: 10.1186/s13045-024-01645-3.

    PubMed 39828738

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Carfilzomib, Dexamethasone and Laboratory Biomarker Analysis in people with Anemia and Recurrent Multiple Myeloma, run by National Cancer Institute (NCI) at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number and severity of adverse events (time frame: Up to 4 weeks post treatment). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02101944, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in